All In Biotech

Drug Trial Radar · NCT01221077

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

A Randomized, Double-Blind, Phase 2 Study of Erlotinib (Tarceva®) in Combination With OSI-906 or Placebo in Chemonaive Patients With Advanced NSCLC With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

88

Actual

Start

Apr 8, 2011

Primary completion

Mar 1, 2013

Study completion Sep 1, 2014

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Oct 14, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, randomized, double-blind, placebo-controlled, phase 2 study of Erlotinib (Tarceva®) in combination with OSI-906 in Patients with Advanced non-small cell lung cancer (NSCLC) with Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene who are Chemonaive.

Conditions

  • NSCLC
  • Non Small Cell Lung Cancer

Interventions

  • OSI-906Drug

    As of 01 March 2013, OSI-906 is no longer being administered

  • ErlotinibDrug

    Erlotinib administered orally

  • PlaceboDrug

    As of 01 March 2013, the matching placebo is no longer being administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival of OSI-906 in combination with Erlotinib or Erlotinib plus placeboTime frame: 15 months

Locations

29 sites in 6 countries. Site status is shown where the registry gives one.

  • University of California, San Diego/Moores Cancer Center

    La Jolla, California

  • H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida

  • Cleveland Clinic Florida

    Weston, Florida

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • Rush University Medical Center

    Chicago, Illinois

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Medical University of South Carolina

    Charleston, South Carolina

  • University of Tennessee Cancer Institute

    Memphis, Tennessee

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Swedish Cancer Institute

    Seattle, Washington

  • Seattle Cancer Care Alliance University of Washington

    Seattle, Washington

  • Juravinski Cancer Centre

    Hamilton, Ontario, Canada

  • London Regional Cancer Program

    London, Ontario, Canada

  • Princess Margaret Hospital

    Toronto, Ontario, Canada

  • Jewish General Hospital

    Montreal, Quebec, Canada

  • Pamela Youde Nethersole Eastern Hospital

    Chai Wan, Hong Kong

  • Oncocare Cancer Center

    Singapore, Singapore

  • Johns Hopkins Singapore International Medical Centre

    Singapore, Singapore

  • Seoul National University Bundang Hospital

    Seongnam-si, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Korea University Anam Hospital

    Seoul, South Korea

  • Chonnam National University Hwasun Hospital

    Ilsimri, Hwasun-gun, South Korea

  • Asan Medical Center

    Songpa-gu, Seoul, South Korea

  • Maharaj Nakorn Chiangmai

    Chiang Mai, Thailand

  • Khon Kaen University

    Khon Kaen, Thailand

  • Songklanagarind Hospital, Prince of Songkla University

    Songkhla, Thailand

  • National Cancer Institute

    Phayathai, Bangkok, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.